High Risk HPV Found in Male Genital Warts; The CBCD Reviews the Medical Evidence
Male patients with genital warts have been shown to be infected with multiple strains of HPV. (1)
It is more likely for those who are already infected with HPV to also become infected with another strain of HPV (low or high risk).
ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, May 10, 2016 /EINPresswire.com/ -- — Greg Bennett, CBCD
“Infected with the human papillomavirus (HPV)? The CBCD recommends taking Gene-Eden-VIR or Novirin.” - Greg Bennett, CBCD
A study showed that men who have genital warts are more likely to be infected with more than one strain of the human papillomavirus. Dr. Kwon and colleagues wrote that “The presence of multiple HPV types was found previously to be the most important risk factor for subsequent acquisition of a new HPV type, recurrence, and cancer progression. Although it has been hypothesized that the acquisition of one HPV type facilitates the acquisition of another type by some yet unknown biological mechanism, it is important that these HPV-positive men who acquired a new type were more likely to acquire multiple HPV types than HPV-negative men.” (1) In other words, it is more likely for those who are already infected with HPV to also become infected with another strain of HPV (low or high risk). “The most consistent determinant of co-infection occurrence (with many types of HPV) was number of sexual partners.” (2)
Click here to learn more about HPV symptoms.
The Center for the Biology of Chronic Disease (CBCD) therefore recommends that HPV infected men take Gene-Eden-VIR or Novirin. The formula of these natural, antiviral products was shown to reduce symptoms associated with HPV infection in two separate post-marketing clinical studies that followed FDA guidelines. Moreover, the formula was designed to help the immune system target the latent HPV virus.
The Center for the Biology of Chronic Disease (CBCD) recommends that HPV infected individuals take Novirin or Gene-Eden-VIR, which have a natural, antiviral formula proven to reduce viral symptoms in two separate post-marketing clinical studies that followed FDA guidelines.
The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)
Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:
http://www.gene-eden-vir.com
and
http://www.novirin.com
Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.
To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.
“The anatomical sites and genotyping methods used for HPV detection have varied across different studies and may have contributed to the observed differences among men in these reports. In our current study, most of the samples were obtained at the penile shaft (75.0%). These findings emphasized the importance of the penile shaft as a site of HPV infection in men, as well as being a site with the most potential for HPV transmission during sexual intercourse. In addition, our finding that samples obtained at the urethra were more likely to have high-risk infection suggests that men with genital warts should undergo urethral examination.” (1)
What Treatments are Available that Target HPV?
“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (3) In contrast, Novirin and Gene-Eden-VIR were designed to target the latent HPV.
The CBCD therefore recommends that HPV infected individuals take Novirin or Gene-Eden-VIR. Learn about Novirin and HPV and Gene-Eden-VIR and HPV.
Find us on Facebook here: https://www.facebook.com/GeneEdenVIR
Follow us on Twitter here: @HananPolansky
References:
(1) Kwon T1, Moon KH1, Yang SH2, Roh MC3, Lee SH4, Kim JW5, Kim IK6, Roh KH7, Park S8. Multiple Human Papillomavirus Infection Is Associated with High-Risk Infection in Male Genital Warts in Ulsan, Korea.J Korean Med Sci. 2016 Mar;31(3):371-5.
(2) Smith MA1, Tellier PP, Roger M, Coutlée F, Franco EL, Richardson H. Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioral and biologic factors. Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):812-22.
(3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 http://dx.doi.org/10.4236/pp.2013.46A001
Greg Bennett
CBCD
585-250-9999
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
